BiotechTube

TNX-102 SL + Placebo SL Tablets

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

PTSD

Conditions

PTSD

Trial Timeline

Mar 7, 2019 → Apr 24, 2020

NCT ID
NCT03841773

About TNX-102 SL + Placebo SL Tablets

TNX-102 SL + Placebo SL Tablets is a phase 3 stage product being developed by Tonix Pharmaceuticals for PTSD. The current trial status is terminated. This product is registered under clinical trial identifier NCT03841773. Target conditions include PTSD.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03841773Phase 3Terminated

Competing Products

11 competing products in PTSD

See all competitors
ProductCompanyStageHype Score
SYN117 (nepicastat) + Placebo comparatorJohnson & JohnsonPhase 2
52
Quetiapine + PlaceboJohnson & JohnsonApproved
85
Lu AG06466 + PlaceboLundbeckPhase 1
30
Mifepristone 1200 mg daily + PlaceboCorcept TherapeuticsPhase 2
47
TNX-102 SLTonix PharmaceuticalsPhase 2
44
TNX-102 SL 5.6 mgTonix PharmaceuticalsPhase 3
69
TNX-102 SL + PlaceboTonix PharmaceuticalsPhase 2
44
TNX-102 SL + Placebo SL TabletTonix PharmaceuticalsPhase 3
69
TNX-102 SL + PlaceboTonix PharmaceuticalsPhase 2
44
TNX-102 SLTonix PharmaceuticalsPhase 3
69
Ganaxolone + PlaceboBrain BiotechPhase 2
44

Other Products from Tonix Pharmaceuticals

TNX-102 SLPhase 3
69
TNX-102 SL 5.6 mgPhase 3
69
TNX-102 SL Tablet, 2.8 mg + Placebo SL TabletPhase 3
69
TNX-102 SL Tablet, 2.8mg + Placebo SL TabletPhase 3
69
TNX-102 SL + Placebo SL TabletPhase 3
69